A controlled one-year trial of dextromethorphan in amyotrophic lateral sclerosis

Clinical Neuropharmacology

Volumn 19, Issue 2, 1996, Pages 189-192

  Blin, O ^a   Azulay, J P ^a   Desnuelle, C ^b   Bille Turc F ^a   Braguer, D ^a   Besse, D ^a   Branger, E ^a   Crevat, A ^a   Serratrice, G ^a   Pouget, J Y ^a  

^a TIMONE HOSPITAL   (France)

^b PASTEUR HOSPITAL   (France)

Author keywords

Amyotrophic lateral sclerosis; Dextromethorphan; Glutamate; N Methyl D aspartate receptors

Indexed keywords

DEXTROMETHORPHAN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT;

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; FUNCTIONAL DISEASE; HUMAN; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SEX RATIO; TREATMENT OUTCOME;

EID: 0007155995     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002826-199619020-00009     Document Type: Article

References (14)

1. Plaitakis A, Caroscio JY. Abnormal glutamate metabolism in amyotrophic lateral sclerosis. Ann Neurol 1987;22:375-9.
2. Hugon J, Tabaraud F, Rigaud M, Vallat JM, Dumas M. Glutamate deshydrogenase and aspartate aminotransferase in leukocytes of patients with motor neuron disease. Neurology 1989;39:956-8.
3. Rothstein JD, Martin IJ, Kunel RW. Decreased glutamate transport by the brain and spinal cord in amyotrophic lateral sclerosis. N Engl J Med 1992;326:1464-8.
4. Plaitakis A, Smith J, Mandelis J, Yahr MD. Pilot trial of branched chain amino acids in amyotrophic lateral sclerosis. Lancet 1988;1:1015-18.
5. Bensimon G, Lacomblez L, Meininger V, and ALS/Riluzole study group. A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med 1994;330:585-91.
6. Choi DW. Glutamate neurotoxicity and diseases for the nervous system. Neuron 1988;1:623-34.
7. Sing B, Coulter D, Choi D, Primer D. Dextrorphan and dextromethorphan common antitussives are antiepileptic and antagonize NMDA in brain slices. Soc Neurosci Abstr 1987;13:1560.
8. Askmark H, Aquilonius SM, Gillberg PG, Liedholm LJ, Stälberg E, Wuopio R. A pilot trial of dextromethorphan in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 1993;56:197-200.
9. El Escorial World Federation of Neurology. Criteria for the diagnosis of amyotrophic lateral sclerosis. J Neurol Sci 1994;124(suppl):96-107.
10. Hollander D, Pradas J, Kaplan R, McLeod H, Evans W, Munsat TL. High-dose dextromethorphan in amyotrophic lateral sclerosis: phase 1 safety and pharmacokinetic studies. Ann Neurol 1994;36:920-4.
11. Lafon-Cazal M, Pietri S, Culcasi M, Bockaert J. NMDA-dependent Superoxide production and neurotoxicity. Nature 1993;364:535-7.
12. Koh MP, Harley J, Hartley DM, Choi DW. Non-NMDA receptor mediated neurotoxicity in cortical culture. J Neurosci 1990;10:693-705.
13. Weiss JH, Choi DW. Slow non-NMDA receptor mediated neurotoxicity and amyotrophic lateral sclerosis. In: Rowland LP, ed. Amyotrophic lateral sclerosis and other motor neuron diseases. New York: Raven Press. 1991:311-18. (Advances in neurology, vol 56)
14. Couratier P, Hugon H, Sindou P, Vallat JM, Dumas M. Cell culture evidence for neuronal degeneration in amyotrophic lateral sclerosis being linked to glutamate AMPA/kainate receptors. Lancet 1993;341:265-8.